Influence of AB0-incompatibility on complications occurrence after allogeneic hematopoietic stem cell transplantation

Abstract

Influence of AB0 incompatibility on complications occur rence after allogeneic hematopoietic stem cell trans plantation Research objective: To assess the impact of AB0 erythrocyte antigens system incompatibility on complications incidence after allogeneic hematopoietic stem cell transplantation (alloHSCT). Patients and methods. The study included 240 patientsrecipients for alloHSCT with oncological and hematological diseases. The median age was 19.0 (1-66) years. The research revealed that overall incidence of acute graft versus host disease (aGVHD) was higher in the case of AB0 incompatibility (p <0.01), and the rate of aGVHD severe forms at AB0 incompatible alloHSCT were observed more often (p = 0.005). At AB0 inco mpatible unrelative alloHSCT risk of aGVHD was higher (81,3 %) compared to the relative alloHSCT (44 %) (p = 0.002). AB0 incompatibility between donor of HSC and the recipient may be a risk factor for aGVHD.

Daratumumab in post-transplantation pure red cell aplasia in adults

“…The selection of a donor of hematopoietic stem cells is based on compatibility of the major histocompatibility complex (HLA) class I and II genes [2], ABO compatibility is usually a minor factor when selecting a donor. As shown in a number of studies, ABO incompatibility does not significantly affect overall and disease-free survival in allo-HSCT [3][4][5][6][7]. However, it can cause a number of serious complications, such as post-transplant pure red cell aplasia (PRCA), leading to a significant deterioration in the patient's somatic status and quality of life [3].…”

“…Three types of ABO incompatibility are discerned, i.e., minor, when the recipient is transfused with graft containing anti-A and anti-B antibodies; major, when the recipient's plasma contains anti-A and anti-B antibodies, and combined incompatibility, with presence of anti-A and anti-B antibodies both in donor graft and recipient's plasma [6]. According to the literature, ABO -incompatible allo-HSCT accounts for 25-50% of all transplantations [6][7][8], with 7-30% of these patients developing PRCA [7,[9][10][11].…”